Schedule 13G
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
 
SCHEDULE 13G
(Rule 13d-102)
 
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2 (b)
 
(Amendment No.        )1
 
 
Northwest Biotherapeutics, Inc.
(Name of Issuer)
 
 
Common Stock, par value $ .001
(Title of Class of Securities)
 
 
66737P105
(CUSIP Number)
 
 
December 9, 2002
(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨        Rule 13d-1 (b)
 
þ        Rule 13d-1 (c)
 
¨        Rule 13d-1 (d)
 
 
 
1
 
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

(Page 1 of 6 Pages)

 
 
CUSIP No. 66737P105
  
13G
  
Page   2   of   6   Pages
 
 
1


     
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
 
Medarex, Inc. (22-2822175)
 
        
2

     
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
  
        (a)  ¨
        (b)  þ
    
3
     
SEC USE ONLY
 
        
4



     
CITIZENSHIP OR PLACE OR ORGANIZATION
 
New Jersey
 
 
        
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
  
5
     
SOLE VOTING POWER        2,800,000
 
6
     
SHARED VOTING POWER
 
7
     
SOLE DISPOSITIVE POWER        2,800,000
 
8
     
SHARED DISPOSITIVE POWER
9
     
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,800,000
         
10
     
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES
  
        ¨
     
11
     
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.7%
         
12
     
TYPE OF REPORTING PERSON*
CO
         
*SEE INSTRUCTIONS BEFORE FILLING OUT!
 

(Page 2 of 6 Pages)

 
Item 1(a).
     
Name of Issuer:
      
Northwest Biotherapeutics, Inc.
Item 1(b).
     
Address of Issuer’s Principal Executive Offices:
      
21720 – 23rd Drive SE
Suite 100
Bothell, Washington 98021
Item 2(a).
     
Name of Person Filing:
      
Medarex, Inc.
Item 2(b).
     
Address of Principal Business Office or, if none, Residence:
      
707 State Road
Suite 206
Princeton, NJ 08540
Item 2(c).
     
Citizenship:
      
New Jersey
Item 2(d).
     
Title of Class of Securities:
      
Common Stock, $ .001 par value
Item 2(e).
     
CUSIP Number:
      
66737P105
Item 3.
     
If This Statement is Filed Pursuant to Rules 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a)
   
¨
   
Broker or dealer registered under Section 15 of the Exchange Act;
(b)
   
¨
   
Bank as defined in Section 3 (a) (6) of the Exchange Act;
(c)
   
¨
   
Insurance company as defined in Section 3 (a) (19) of the Exchange Act;
(d)
   
¨
   
Investment company registered under Section 8 of the Investment Company Act;
(e)
   
¨
   
An Investment Adviser in accordance with Rule 13d-1 (b) (1) (ii) (E);
 

(Page 3 of 6 Pages)

 
(f)
   
¨
   
An employee benefit plan or endowment fund in accordance with Rule 13d-1 (b) (1) (ii) (F);
(g)
   
¨
   
A parent holding company or control person in accordance with Rule 13d-1 (b) (ii) (G);
(h)
   
¨
   
A savings association as defined in Section 3 (b) of the Federal Deposit Insurance Act;
(i)
   
¨
   
A church plan that is excluded from the definition of an investment company under Section 3 (c) (14) of the Investment Company Act;
(j)
   
¨
   
Group, in accordance with Rule 13d-1 (b) (1) (ii) (J)
 
 
Item 4.
   
Ownership.
(a)
   
Amount Beneficially Owned:
   
2,800,000
(b)
   
Percent of Class:
   
14.7%
(c)
   
Number of shares as to which such person has:
     
    
(i)       sole power to vote or to direct the vote:
   
2,800,000
    
(ii)      shared power to vote or direct the vote:
     
    
(iii)     sole power to dispose or to direct the disposition of:
   
2,800,000
    
(iv)     shared power to dispose or to direct the disposition of:
     
           
Item 5.
   
Ownership of Five Percent or Less of a Class.
    
Not applicable
Item 6.
   
Ownership of More than Five Percent on Behalf of Another Person.
    
Not applicable
Item 7.
   
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    
Not applicable
 

(Page 4 of 6 Pages)

 
Item 8.
   
Identification and Classification of Members of the Group.
    
Not applicable
Item 9.
   
Notice of Dissolution of Group.
    
Not applicable
Item 10.
   
Certifications.
    
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

(Page 5 of 6 Pages)

 
SIGNATURE
 
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
December 17, 2002
(Date)
/s/    Christian S. Schade
(Signature)
Christian S. Schade, Senior Vice President, Finance and Administration, and Chief Financial Officer
(Name/Title)

(Page 6 of 6 Pages)